SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:uu-325334"
 

Sökning: id:"swepub:oai:DiVA.org:uu-325334" > Cetuximab in treatm...

  • Guren, Tormod KyrreOslo Univ Hosp, Dept Oncol, Oslo, Norway.;KG Jebsen Colorectal Canc Res Ctr, Oslo, Norway. (författare)

Cetuximab in treatment of metastatic colorectal cancer : final survival analyses and extended RAS data from the NORDIC-VII study

  • Artikel/kapitelEngelska2017

Förlag, utgivningsår, omfång ...

  • 2017-04-11
  • NATURE PUBLISHING GROUP,2017
  • electronicrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:uu-325334
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-325334URI
  • https://doi.org/10.1038/bjc.2017.93DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Background: The NORDIC-VII study is a randomised phase III trial of cetuximab plus continuous or intermittent fluorouracil, folinic acid, and oxaliplatin (Nordic FLOX) vs FLOX alone in first-line treatment of metastatic colorectal cancer. The present report presents an updated and final survival analysis with BRAF and extended RAS mutational status, 5 years after the primary analysis.Methods: A total of 566 patients were included in the intention-to-treat (ITT) population of the NORDIC-VII study. Updated survival status was obtained from 176 patients who were alive in the primary survival analyses. Samples from 223 tumours previously found to be KRAS (exon 2) and BRAF (V600E) wild-type, were re-analysed for KRAS (exons 3 and 4) and NRAS (exons 2-4) mutations.Results: Including the extended RAS analyses, RAS and BRAF mutational status was available from 457 patients (81% of the ITT population). RAS was mutated in 46% and BRAF in 12% of the tumours. RAS and BRAF, if mutated, were negative prognostic factors. The updated analyses confirmed the finding of the primary report that cetuximab did not provide any additional benefit when added to FLOX in patients with RAS/BRAF wild-type tumours, neither on progression-free nor overall survival. However, the outcomes in a subset of patients, which, after the first eight treatment cycles, received cetuximab alone, suggested a beneficial effect of cetuximab monotherapy.Conclusions: Adding cetuximab to Nordic FLOX did not provide any clinical benefit, but the data suggested an effect of cetuximab monotherapy in patients with RAS/BRAF wild-type tumours in the NORDIC-VII cohort. The data were compatible with a negative interaction between cetuximab and the Nordic FLOX chemotherapy backbone.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Thomsen, MariaOslo Univ Hosp, Dept Oncol, Oslo, Norway.;Univ Oslo, Fac Med, Inst Clin Med, Oslo, Norway. (författare)
  • Kure, Elin H.Oslo Univ Hosp, Inst Canc Res, Dept Canc Genet, Oslo, Norway. (författare)
  • Sorbye, HalfdanHaukeland Hosp, Dept Oncol, Bergen, Norway.;Univ Bergen, Dept Clin Sci, Bergen, Norway. (författare)
  • Glimelius, BengtUppsala universitet,Experimentell och klinisk onkologi(Swepub:uu)bengglim (författare)
  • Pfeiffer, PerOdense Univ Hosp, Dept Oncol, Odense, Denmark.;Univ Southern Denmark, Inst Clin Res, Odense, Denmark. (författare)
  • Osterlund, PiaTampere Univ Hosp, Dept Oncol, Tampere, Finland. (författare)
  • Sigurdsson, FridbjornLandspitali, Dept Oncol, Reykjavik, Iceland. (författare)
  • Lothe, Inger Marie BowitzOslo Univ Hosp, Dept Pathol, Oslo, Norway. (författare)
  • Dalsgaard, Astrid MarieUniv Oslo, Fac Med, Inst Clin Med, Oslo, Norway. (författare)
  • Skovlund, EvaNorwegian Univ Sci & Technol, Dept Publ Hlth & Nursing, Trondheim, Norway. (författare)
  • Christoffersen, ThoralfUniv Oslo, Fac Med, Inst Clin Med, Dept Pharmacol, Oslo, Norway. (författare)
  • Tveit, Kjell MagneOslo Univ Hosp, Dept Oncol, Oslo, Norway.;KG Jebsen Colorectal Canc Res Ctr, Oslo, Norway.;Univ Oslo, Fac Med, Inst Clin Med, Oslo, Norway. (författare)
  • Oslo Univ Hosp, Dept Oncol, Oslo, Norway.;KG Jebsen Colorectal Canc Res Ctr, Oslo, Norway.Oslo Univ Hosp, Dept Oncol, Oslo, Norway.;Univ Oslo, Fac Med, Inst Clin Med, Oslo, Norway. (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:British Journal of Cancer: NATURE PUBLISHING GROUP116:10, s. 1271-12780007-09201532-1827

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy